Vanguard Group Inc Candel Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,339,150 shares of CADL stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,339,150
Previous 946,265
41.52%
Holding current value
$14.7 Million
Previous $6.56 Million
77.26%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CADL
# of Institutions
77Shares Held
15.6MCall Options Held
981KPut Options Held
521K-
Baker Bros. Advisors LP New York, NY2.98MShares$32.7 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$21.3 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$21.2 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$17.5 Million0.78% of portfolio
-
Black Rock Inc. New York, NY823KShares$9.02 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $317M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...